InterMune Inc. (ITMN) announced Tuesday morning that the on-going Phase 2b study conducted by Roche of ITMN-191 combined with standard of care PEGASYS and COPEGUS in HCV treatment-naive patients has been modified.
InterMune gapped down sharply Tuesday, but has since traded in a narrow range. The stock has slipped further in the last 10 minutes and is now down 2.31 at $11.71 on the highest volume in 6 months. InterMune has dropped to a 5 1/2 month low.
For comments and feedback: editorial@rttnews.com